Posts for Cyclo Therapeutics, Inc. ($CYTHW)

CTD Holdings, Inc. announces record revenue of $441,909 for Q1 2012. Explore financial insights and details in this 8-K report.

CTD Holdings, Inc. reports a strategic acquisition of a 6,280 sq. ft. property for $471K. Details on financing and future operational plans included.

CTD Holdings, Inc. filed an 8-K on March 20, 2017, reporting the resignation of director George L. Fails effective April 1, 2017. Insights on potential management changes included.

Explore Cyclo Therapeutics, Inc.'s latest 8-K report detailing stock and warrant activities as of May 2, 2023. Essential insights for investors and analysts on CYTH and CYTHW.

Discover Cyclo Therapeutics, Inc.'s latest 8-K report filed on October 20, 2023, detailing stock and warrant info for investors. Key data on equity structure and compliance included.

Explore CTD Holdings, Inc.'s December 2016 report detailing a $980,000 asset sale, debt repayment, and strategic financial maneuvers for operational growth.

CTD Holdings, Inc. reveals a $500,000 share bonus for CEO Rick Strattan and new consulting agreements to seek acquisitions. Key insights into executive compensation and strategy.

CTD Holdings, Inc. reports the appointment of Dr. Jeffrey L. Tate to its Board of Directors, detailing his extensive qualifications and compensation agreements.

Explore CTD Holdings, Inc.'s May 23, 2018, shareholder meeting results, including significant amendments to its Articles of Incorporation, boosting authorized common shares.

CTD Holdings, Inc. announces the retention of Torreya Capital, LLC as a strategic advisor for business development. Key insights on growth and management involvement in the 8-K report.

Explore CTD Holdings, Inc.'s latest 8-K filing detailing N. Scott Fine's new role as Vice Chair and board committee restructuring. Key governance updates as of May 16, 2014.

CTD Holdings, Inc. announces promising preliminary data on Trappsol® Cyclo™ for Niemann-Pick disease type C, showing its ability to cross the blood-brain barrier. Key clinical trial insights.